Magellan Healthcare Releases Clinical Monograph: Appropriate Use of Psychotropic Drugs in Children and Adolescents
March 22 2022 - 5:30AM
Business Wire
Magellan Healthcare, the behavioral and specialty healthcare
segment of Magellan Health, Inc., published its updated clinical
monograph: Appropriate Use of Psychotropic Drugs in Children and
Adolescents.
As the country addresses the mental health crisis impacting
children and adolescents, Magellan offers its clinical monograph
highlighting evidence-based research on the use of
psychotherapeutic agents in children and principles for optimal
children’s psychopharmacotherapy practice–that underpins its model
of care for serving children, youth and their families. The
monograph serves as a resource for providers, clients, parents and
other stakeholders to be informed and support decision making on
behavioral health treatment options for children and
adolescents.
In the face of increasing rates of psychotropic drug prescribing
in the treatment of young people, Magellan’s monograph provides an
in-depth analysis and outlines the need for:
- Improved collaborative care for children’s behavioral
health
- Increased use of non-pharmacologic interventions for youth in
general and foster care youth in particular
- Consistent approaches to assessment, diagnosis, treatment,
oversight and monitoring
- Active family participation and understanding of the child’s
illness and challenges they face
“Magellan is proud to contribute this valuable compendium of
information and research as we demonstrate a continued commitment
to children’s behavioral health and addressing the national
children’s mental health crisis,” said Magellan Healthcare Medical
Director Louis Parrott, M.D., Ph.D., and the monograph’s lead
author. “Now, more than ever, the behavioral health treatment
options for our children and youth must be evidence-based. Our
monograph supports this notion through packaging the most
up-to-date evidence-based research to serve as a reference for
providers and families in making informed and safe decisions on the
use of psychotropic drugs in kids.”
The January 2022 revision covers the following topics, and
provides an updated listing of psychotropic drugs, and associated
information, commonly prescribed for children:
- Nature and scope of the problem
- Children in foster care
- Controversies in clinical management
- Principles for optimal psychopharmacotherapy practice
- Research evidence for treatment efficacy of psychotherapeutic
agents, including mood disorders, obsessive-compulsive disorder,
anxiety disorders, post-traumatic stress disorder, disruptive
behavioral disorders/aggression, attention-deficit/hyperactivity
disorder, developmental disabilities and eating disorders
- Drug treatment effects on nervous system development
This resource is available along with Magellan’s award-winning
monograph, Understanding and Meeting the Needs of Children and
Adolescents at High Risk: Foundations of a Model, which highlights
evidence-based prevention and treatment approaches for problematic
behaviors and various types of behavioral health challenges in
children and adolescents. Both provide valuable insights and
information to support the critical behavioral health needs of our
nation’s children.
Learn more and access the monographs and overview documents at
MagellanHealthcare.com/Monographs.
About Magellan Healthcare: Magellan Healthcare, Inc., the
healthcare business unit of Magellan Health, Inc., offers solutions
for complex conditions in the areas of behavioral health and
medical specialty treatment. Magellan Healthcare serves commercial
health plans, employers, state and local governments, and the
Federal government, including the Department of Defense. For more
information, visit MagellanHealthcare.com.
About Magellan Health: Magellan Health, Inc. is a leader
in managing the fastest growing, most complex areas of health,
including special populations, complete pharmacy benefits and other
specialty areas of healthcare. Magellan supports innovative ways of
accessing better health through technology, while remaining focused
on the critical personal relationships that are necessary to
achieve a healthy, vibrant life. Magellan's customers include
health plans and other managed care organizations, employers, labor
unions, various military and governmental agencies and third-party
administrators. For more information, visit MagellanHealth.com.
(MGLN-GEN)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220322005264/en/
Media Contact: Lilly Ackley, ackleyl@magellanhealth.com,
(860) 507-1923
Magellan Health (NASDAQ:MGLN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Magellan Health (NASDAQ:MGLN)
Historical Stock Chart
From Dec 2023 to Dec 2024